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Background: Recent data suggest that cancer stem cells (CSCs) play an important role in cancer, as these cells
possess enhanced tumor-forming capabilities and are responsible for relapses after apparently curative therapies
have been undertaken. Hence, novel cancer therapies will be needed to test for both tumor regression and CSC
targeting. The use of oncolytic vaccinia virus (VACV) represents an attractive anti-tumor approach and is currently
under evaluation in clinical trials. The purpose of this study was to demonstrate whether VACV does kill CSCs that
are resistant to irradiation and chemotherapy.
Methods: Cancer stem-like cells were identified and separated from the human breast cancer cell line GI-101A by
virtue of increased aldehyde dehydrogenase 1 (ALDH1) activity as assessed by the ALDEFLUOR assay and cancer
stem cell-like features such as chemo-resistance, irradiation-resistance and tumor-initiating were confirmed in cell
culture and in animal models. VACV treatments were applied to both ALDEFLUOR-positive cells in cell culture and
in xenograft tumors derived from these cells. Moreover, we identified and isolated CD44+CD24+ESA+ cells from
GI-101A upon an epithelial-mesenchymal transition (EMT). These cells were similarly characterized both in cell
culture and in animal models.
Results: We demonstrated for the first time that the oncolytic VACV GLV-1h68 strain replicated more efficiently in
cells with higher ALDH1 activity that possessed stem cell-like features than in cells with lower ALDH1 activity.
GLV-1h68 selectively colonized and eventually eradicated xenograft tumors originating from cells with higher
ALDH1 activity. Furthermore, GLV-1h68 also showed preferential replication in CD44+CD24+ESA+ cells derived from
GI-101A upon an EMT induction as well as in xenograft tumors originating from these cells that were more
tumorigenic than CD44+CD24-ESA+ cells.
Conclusions: Taken together, our findings indicate that GLV-1h68 efficiently replicates and kills cancer stem-like
cells. Thus, GLV-1h68 may become a promising agent for eradicating both primary and metastatic tumors,
especially tumors harboring cancer stem-like cells that are resistant to chemo and/or radiotherapy and may be
responsible for recurrence of tumors.
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There is an increasing body of knowledge that human
breast cancers are driven by a tumor-initiating “cancer
stem cells” (CSCs) component that may contribute to
tumor metastases and therapeutic resistance [1-5]. Breast
CSCs were initially characterized as CD44+/CD24−/lin−
cells that were capable of serial transplantation in non-
obese/severe combined immunodeficient (NOD/SCID)
mice [6]. In addition to these markers, Ginestier et.al have
recently shown that cells with stem cell properties in both
normal and malignant breast samples can be identified by
the expression of the enzyme aldehyde dehydrogenase 1
(ALDH1). By using flow cytometry and the ALDEFLUOR
assay that measures ALDH1 activity, CSCs were isolated
from primary human mammary carcinomas grown as
xenografts in NOD/SCID mice. In addition, ALDH1
immunostaining identified both normal and malignant
stem cells in situ in fixed paraffin embedded sections [7].
Furthermore, recent data suggests that immortalized cell
lines derived from both murine and human tissues may
also contain a cellular population displaying stem cell
properties [8-11]. By analyzing thirty-three breast cancer
cell lines, Charafe-Jauffret et al. confirmed the hierarchical
organization of immortalized cell lines and identified
ALDH1 as a potential stem cell marker and therapeutic
target [12].
Recently, the involvement of an Epithelial-Mesenchymal
Transition (EMT) in the metastatic dissemination of epi-
thelial cancer cells has emerged in cancer biology as a
novel concept. Using a mammary tumor progression
model, it was shown that cells possessing both stem and
tumorigenic characteristics of CSCs can be derived from
human mammary epithelial cells following the activation
of the Ras-MAPK pathway and that the acquisition of stem
and tumorigenic characters is driven by EMT induction
[13,14]. Moreover, the EMT cell model has successfully
been utilized for screening for agents with mammary epi-
thelial CSCs-specific toxicity [15].
Advances in cancer research has resulted in increased
detection, improved treatments and enhanced prevention
of metastases. Despite these advances, however, metastatic
cancers are generally resistant to conventional therapeutics
and the prognosis is poor. Therefore, there is an urgent
need for the development of new therapies and novel
approaches which target cancer metastases. A growing
body of scientific evidence indicates that oncolytic vaccinia
viruses (VACVs) carrying imaging genes may represent a
new treatment strategy that combines tumor site-specific
therapeutics with diagnostics (theranostics) [16].
The human breast cancer cell line GI-101A was widely
used as a model for testing oncolytic VACV theranostics in
our groups [17-24]. To demonstrate the efficacy of vaccinia
virotherapy against cancer stem-like cells, we isolated
ALDEFLUOR-positive and ALDEFLUOR-negative cellsfrom GI-101A cells and applied the viral treatment to these
cells. The evidence from cell culture and tumor xenograft
studies indicated that GI-101A-derived ALDEFLUOR-
positive cells possessed CSC properties. Compared to
ALDEFLUOR-negative cells, the oncolytic VACV GLV-1h68
strain showed enhanced replication in the ALDEFLUOR-
positive cells and was also able to eradicate the xenograft
tumors derived from ALDEFLUOR-positive cells. Moreover,
we isolated CD44+CD24+ESA+ and CD44+CD24-ESA+
cells from GI-101A cell line upon an EMT induction.
The CD44+CD24+ESA+ cells demonstrated increased
tumorigenicity than CD44+CD24-ESA+ cells. Interest-
ingly, GLV-1h68 strain showed enhanced replication in
CD44+CD24+ESA+ cells in contrast to CD44+CD24-ESA+
cells and better therapeutic efficacy in the xenograft
tumors derived from the CD44+CD24+ESA+cells.
Methods
Cell culture
Human breast cancer cell lines (MCF-7, MDA-MB-231,
and HS578T) and African green monkey kidney fibroblasts
(CV-1) were obtained from the American Type Culture
Collection (ATCC). SUM149PT was purchased from
Asterand, PLC (Detroit, MI). The cell line GI-101A, a
highly metastatic derivative of GI-101 human ductal
adenocarcinoma [25-27], was kindly provided by Dr. A. Aller
(Rumbaugh-Goodwin Institute for Cancer Research, Inc.).
The cell lines were grown under the recommended culture
conditions (Additional file 1: Table S1, Additional file 2:
Figure S2). All experiments were done with semi-confluent
cells in the exponential phase of growth. Immortalized
human mammary epithelial cells (HMLE) were kindly pro-
vided and cultured as recommended by Dr. R.A. Weinberg
(Whitehead Institute, Cambridge, MA). HMLE were cul-
tured in 1:1 Dulbecco’s Modified Eagle’s Medium
(DMEM)/F12 medium (Cellgro) complemented with 10%
FBS (Cellgro), 100 U/ml penicillin-streptomycin (Cellgro),
2 mM/L glutamine (Cellgro), 10 ng/ml human epidermal
growth factor (EGF) (Stemgent), 0.5 mg/ml hydrocortisone
(Lonza) and 10 mg/ml insulin (Sigma). EMT was induced
with additional 10 ng/ml recombinant human transform-
ing growth factor (TGF-β1) (Stemgent) for 12 days. Similar
culture condition was utilized to induce EMT in GI-101A
cells.
ALDEFLUOR assay and isolation of the
ALDEFLUOR-positive cell population by
fluorescence-activated cell sorting
ALDH1 activity was assessed in five human breast cancer
cell lines using the ALDEFLUOR kit (StemCell Technolo-
gies). The population with higher ALDH1 enzymatic activ-
ity was isolated using a FACSAria™ III (Becton Dickinson),
as previously described [7], and analyzed using Cell Lab
Quanta™ SC MPL (Beckman Coulter). Briefly, 1 × 106 cells
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ing ALDH1 substrate (1 × 10-6 M). In each experiment, a
sample of cells was stained under identical conditions in
the presence of 50 mM diethylaminobenzaldehyde, a spe-
cific ALDH1 inhibitor, as a negative control. The electronic
sorting gates were set to exclude dead cells, doublets and
aggregates. After sorting, the purity of sorted populations
was examined using a double sorting of 10,000
ALDEFLUOR-positive and ALDEFLUOR-negative cells.
The sorted ALDEFLUOR-positive population contained
>80% of ALDEFLUOR-positive cells. On contrast, no
ALDEFLUOR-positive cells were detected in the
ALDEFLUOR-negative population.
EMT induction assay and isolation of the CD44+CD24+ESA+
population by fluorescence-activated cell sorting
For EMT induction, HMLE and GI-101A cell lines were
treated with EGF and TGF-β1 as described previously. The
immunostaining was performed using the following anti-
bodies against EMT markers: anti-E-cadherin (clone 36)
(BD Transduction Laboratories), anti-Vimentin (clone
V9) (Sigma) and anti-Fibronectin (clone 10) (BD Trans-
duction Laboratories). Identification and sorting of
CD44+CD24+ESA+ and CD44+CD24-ESA+ were per-
formed using anti-human monoclonal antibodies such as
anti-CD44-APC (clone G44-26) (BD Pharmingen), anti-
CD24-PE (clone ML5) (BD Pharmingen) and anti-ESA-
FITC (clone VU-1D9) (StemCell Technologies) on a BD
FACSAria™ III cell sorter as described by the manufacturer.
Flow cytometry
Nonconfluent cell cultures were trypsinized and the cell
concentration was determined. Then the single cell sus-
pension was washed with 1 × DPBS (Mediatech), and
stained with antibodies recognizing human cell surface
markers such as anti-CD44-APC (clone G44-26) (BD Phar-
mingen), anti-CD24-FITC (clone ML5) (BD Pharmingen),
and anti-CD49f-PE (clone GoH3) (BD Pharmingen). Ap-
proximately 10,000 cells were incubated with antibodies
for 30 minutes at room temperature according to manu-
facturer’s instructions. The unbound antibodies were
washed off and cells were analyzed within 1 hour after
staining on a BD FACSAria™ III (Becton Dickinson). All
flow cytometry data were analyzed by Flowjo software
(Treestar).
Animal models and testing for tumorigenicity
Tumorigenicity of GI-101A ALDEFLUOR-positive and
ALDEFLUOR-negative cells or CD44+CD24+ESA+ and
CD44+CD24-ESA+ cells were assessed by measuring the ef-
ficiency of tumor formation in the abdominal mammary
gland fat pad of 6–8 weeks old athymic nude mice (NCI/
Hsd/Athymic Nude-Foxn1nu, Harlan). After sorting, the
limiting dilutions (50,000, 5,000, and 500 cells) of theALDEFLUOR-positive and ALDEFLUOR-negative popula-
tion or 10,000 and 1,000 cells of CD44+CD24+ESA+ and
CD44+CD24-ESA+ population of GI-101A cells were
mixed with Matrigel (BD Biosciences; 1:1) and implanted
to the mammary fat pads. Tumor growth was recorded
weekly in two dimensions using a digital caliper. Tumor
volume was calculated as [(length × width × width)/2] and
reported in cubic millimeter. All animal experiments were
conducted in accordance with accepted standards of hu-
mane animal care and all experiments were approved by
the Animal Care and Use Committee at Explora Biolabs
(San Diego Science Center).
Virotherapy of GI-101A ALDEFLUOR or CD44+CD24+ESA+
xenograft tumors with GLV-1h68 strain
To assess the response of GI-101A tumors derived from
ALDEFLUOR-positive and ALDEFLUOR-negative cells and
derived from CD44+CD24+ESA+ and CD44+CD24-ESA+
cells, tumor colonization experiments with retro-orbitally
injected GLV-1h68 strain in nude mice were carried out.
12 weeks after implantation of 5,000 ALDEFLUOR sorted
cells or 22 weeks after implantation of 10,000 marker-sorted
cells, a single dose of GLV-1h68 strains (5 × 106 pfu in
100 μL 1 × DPBS) was retro-orbitally injected into tumor-
bearing mice. A total of 30 mice, 5 for each dose group,
were included in this study. Tumor measurements were
recorded weekly for 7 weeks after initial virus injection, in
parallel with fluorescence imaging of tumors.
Anchorage-independent culture of tumor cells
ALDEFLUOR-positive and ALDELFUOR-negative cells from
GI-101A were plated as single cells in 96-well ultra-low at-
tachment plates (Corning) at different densities (1, 10, and
100 viable cells/well). Cells were grown in MammoCult
W
human medium Kit (StemCell Technologies) for 12 days
as described [28]. The capacity of cells to form mammo-
spheres was quantified using ImageJ software (NIH, USA).
Cytotoxicity of drugs in cell cultures
Fluorouracil (5-FU), cis-Diammine (1, 1-cyclobutanedicarboxylato)
platinum (II) (Carboplatin), cis-diamminedichloroplatinum
(II) (CDDP) (Cisplatin), Mitomycin C and Salinomycin were
purchased from Sigma Aldrich; 3-(4, 5-Dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (MTT) cellular proliferation
assays were used for quantitation of chemo-cytotoxicity as
described [18]. ALDEFLUOR-positive and ALDELFUOR-
negative cells (50,000) from GI-101A were plated in 96-
well plates in growth medium overnight and, thereafter, in
serum-free medium. Cells were exposed to increasing con-
centrations (10-9, 10-8, 10-7, 10-6, 10-5, 10-4 M) of drugs
(diluted in DMSO) for 96 hours, followed by the removal
of media and the addition of 500 μL MTT (2.5 mg/mL) in
RMPI without phenol red, for further culturing at 37°C
and 5% CO2 for 4 hours . MTT solution was then removed
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The samples (3 × 100 μL) were transferred to a 96-well
plate and the absorbance was determined at 570 nm, as
well as 650 nm in a SpectraMax M5 plate reader (Molecu-
lar Devices). Cell survival was calculated using the follow-
ing formula: % cell survival = (absorbance value of treated
cells/absorbance value of untreated control cells) × 100%.
Tumor cell sensitivity to irradiation
For clonogenic assays, ALDEFLUOR-positive and
ALDELFUOR-negative cells (105 cells/mL) from GI-101A
were irradiated at room temperature with a RS 2000 X-ray
Biological Irradiator (Rad Source Technologies, Inc) at a
dose rate of 4.95 Gy/minute. A dose curve of 0, 0.5, 1, 2,
and 4 Gy was also generated. All controls were sham irra-
diated. To determine cell survival, colony forming assays
were performed immediately after irradiation by plating
cells in triplicate into 6-well plates. After a growth period
of 28 days, cells were fixed with 75% ethanol and stained
with 1% crystal violet, and colonies containing more than
50 cells were counted.
Cell invasion assays
Invasion assays were done using Cultrex
W
96-well Base-
ment Membrane Extract (BME) Cell Invasion Assay (Tre-
vigen). Briefly, triplicate transwell chambers with 8-μm
pore polycarbonate filters were coated with 50 μL of ice-
cold 0.5× BME in DMEM/F12 and incubated for one hour
at 37°C. Then cells in 200 μL of serum-free medium were
added to the upper chamber. To monitor cell migration,
5,000 cells were seeded on the BME-coated filters and the
lower chamber was filled with 600 μL of medium without
or supplemented with 10% fetal bovine serum (Cellgro).
After incubation for 48 hours, the cells on the underside of
the filter were quantified by using Calcein-AM according
to the assay kit manual.
Viral replication in cell cultures
Sorted ALDEFLUOR-positive and ALDELFUOR-negative GI-
101A cells (1 × 105) or CD44+CD24+ESA+ and CD44+CD24-
ESA+ cells (1 × 105) were seeded into 24-well plates in trip-
licate and were infected with GLV-1h68 strain at an MOI
of 10 or 0.01. The cells were incubated at 37°C for 1 hour
with brief agitation every 10 minutes to aid infection. Then
the infection medium was removed and cells were incu-
bated in fresh growth medium until cell harvest at 1, 12,
24, 48, 72 hours post infection. Viral particles from the
infected cells were released by performing a quick freeze-
thaw cycle and the titers determined by plaque assays in
CV-1 cell monolayers and recorded as plaque forming
units (pfu)/million cells in duplicate. For the infection of
EMT cells, HMLE and GI-101A cells were infected with
GLV-1h68 or GLV-1h190 strain at an MOI of 10 after
12 day EMT induction. After incubation at 37°C for 1 hour,the infection medium was removed and replaced with
fresh growth medium. Virus infection was monitored at
different time points by taking images of same cells under
a fluorescence microscope.
Statistical analysis
Results are presented as the mean ± standard deviation,
calculated from a minimum of three repeated individual
experiments for each group. Statistical analyses were done
with SPSS (version 10, SPSS, Inc.). The comparisons
among treatment groups were made using ANOVA, and
the differences between groups were analyzed using LSD
test when the ANOVA showed an overall significance.
Statistical analysis of survival time was assessed using the
log-rank test. P values of <0.05 were considered significant.
Results
Isolation and tumorigenicity of ALDEFLUOR-positive,
cancer stem-like cells from GI-101A breast cancer cell line
The enzyme ALDH1 is a useful marker for isolating
healthy human mammary stem cells, progenitor cells as
well as transformed tumor-initiating stem cells [12]. The
cancer stem-like cells are isolated by virtue of their expres-
sion of ALDH1 activity, as assessed by flow cytometry
using the ALDEFLUOR assay. To determine whether
human breast cancer cell lines contain an ALDEFLUOR-
positive population, we analyzed five cell lines of GI-101A,
MCF-7, MDA-MB-231, Hs 578 T and SUM149PT, using
the ALDEFLUOR assay. In each cell line, we identified an
ALDEFLUOR-positive fraction in the size of 6.43 ± 0.98%,
0.28 ± 0.06%, 1.74 ± 0.35%, 1.45 ± 0.26% and 18.35 ± 6.54%
of the total viable cell population, respectively (Additional
file 3: Figure S3). We stained adherent GI-101A cells in
plates with ALDEFLUOR present or absent of diethylami-
nobenzaldehyde (DEAB), an inhibitor of ALDH1 to con-
firm the flow cytometry results. The fluorescent images
indicated the presence of ALDEFLUOR-positive cells in
GI-101A and treatment with DEAB reduced ALDH1 ac-
tivity (Additional file 4: Figure S4). We sorted GI-101A
cells for the ALDEFLUOR-positive and ALDEFLUOR-
negative populations (Figure 1A-F) by incubating the cells
with a fluorescent ALDEFLUOR substrate BODIPY-
aminoacetaldehyde (BAAA) and with DEAB, the specific
inhibitor of ALDH1 enzyme. The experiment was used to
establish the fluorescence baseline of ALDH1- cells and to
define the ALDEFLUOR-positive area (ALDH1+)
(Figure 1E). We found that incubation of cells with
ALDEFLUOR in the absence of DEAB caused a shift in
BAAA fluorescence, which defined the ALDEFLUOR-
positive cell population (Figure 1D). ALDH1+ and
ALDH1- cells were separated under sterile conditions in
order to test the tumorigenic potential of GI-101A
ALDEFLUOR-positive cells in nude mice mammary fat
pad xenografts and in cell culture by mammosphere
Figure 1 ALDEFLUOR-positive cell population from GI-101A cells displays properties of CSCs in both cell culture and animal models.
(A-F) Representative FACS sorting of ALDEFLUOR-positive cells from GI-101A cell line. The ALDEFLUOR sorting on GI-101A cells was electronically
gated firstly to exclude dead cells (R1), doublets (R2) and aggregates (R3). Incubation of cells with ALDEFLUOR substrate in the absence of DEAB
induces a shift in BAAA fluorescence, defining the ALDEFLUOR-positive population, which represents 6.43 ± 0.98% of the total live single cells in
GI-101A comparing 0.35 ± 0.98% of the total live single cells in the presence of DEAB. The purity of sorted cells was checked finally. (G-L) The
ALDEFLUOR-positive cells have higher tumorigenic potential and latency in athymic nude mice. Tumor-forming occurrence was observed at
different time points (G-J). (K) Representative tumor development in nude mouse at the ALDEFLUOR-positive cells’ injection site (50,000 cells
injected). Smaller tumor was detected at the ALDEFLUOR-negative cells’ injection site (50,000 cells injected). (L) Tumor growth was monitored
weekly by measuring the tumor volume of five mice in each group. The curves were plotted for the numbers of cells injected (50,000 cells and
5,000 cells) and for each population (ALDEFLUOR-positive, ALDEFLUOR-negative). Tumor growth kinetics correlated with the latency and size of
tumor formation and the number of ALDEFLUOR-positive cells. No tumor was detected when 500 cells were injected, whereas
ALDEFLUOR-positive cells produced tumors that grew at a rate that directly correlated with the number of cells injected. (M) Statistical evaluation
of the mammospheres formation efficiency of GI-101A ALDEFLEOR-positive and ALDEFLEOR-negative cells.
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positive and ALDEFLUOR-negative cells from GI-101A
were tested by inoculating escalating doses of cells (500,
5,000, and 50,000 cells) into mammary fat pads of nude
mice. Tumors were detected in mice injected with 50,000
ALDEFLUOR-positive cells as early as five weeks after cell
implantation (Figure 1G). ALDEFLUOR-positive cells
showed the highest frequency of tumor formation in all
times examined (Figure 1H-J). In addition, tumors origin-
ating from the ALDEFLUOR-positive cell implantations
were much larger than tumors originating from the
ALDEFLUOR-negative cells (Figure 1K). The tumor size
and latency of tumor formation correlated well with the
number of cells injected (Figure 1L). Remarkably, 50,000
and 5,000 ALDEFLUOR-positive cells generated tumors
more efficiently than ALDEFLUOR-negative cells. In con-
trast, we did not see tumors at the 500 cell implantation
dose with either ALDEFLUOR-positive or ALDEFLUOR-
negative cells. For further characterization, ALDEFLUOR-
positive and ALDEFLUOR-negative cells were plated in
96-well ultra-low attachment plates in serum-free medium
containing 10 ng/ml EGF and 20 ng/ml bFGF to monitormammospheres growth under a light microscope. Data
obtained indicate that GI-101A ALDEFLUOR-positive cells
showed two-fold higher mammosphere formation effi-
ciency as did ALDEFLUOR-negative cells (Figure 1M).ALDEFLUOR-positive cells upon culture resemble the
parental cell line GI-101A
The abilities of self-renewal and differentiation into hetero-
geneous cell types are the definition of stem cells, which
are thought to be functionally mimicked by cancer stem
cells [2,29-32]. To assess the capability of cancer stem-like
cells to differentiate and reconstitute the composition of a
parental cell line, the sorted ALDEFLUOR-positive cells
were plated and allowed to expand in cell culture for
12 days. The growing cells were then analyzed for ALDH1
activity by flow cytometry (Figure 2). We found that cul-
tures started with sorted ALDEFLUOR-positive cells
resembled the parental cell line after being continuously
passaged for three times. In terms of ALDH1 activity, it
can be seen that the percentage of ALDEFLUOR-positive
cells decreased from 82.8% to 18.9% after three passages in
Figure 2 Expansion and passage of ALDEFLUOR-positive cells results reconstitution of original GI-101A parental cell line. The sorted
ALDEFLUOR-positive cells were seeded in 6-well plates at 5 × 105 cells/well and passaged every three days. The cellular outgrowths were
re-analyzed in each passage by flow cytometry to assess the reconstitution of parent cell line.
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stem-like cells lose their stem cell marker in cell culture.ALDEFLUOR-positive cells exhibited enhanced resistance
to chemo- and irradiation treatment when compared to
ALDEFLUOR-negative cells
It was reported that cancer stem cells in primary human
leukemia and glioblastoma are resistant to chemotherapy
[33,34]. To document that breast cancer cell line derived
cancer stem-like cells are also resistant to chemothera-
peutic agents. We treated ALDEFLUOR-positive and
ALDEFLUOR-negative cells with increasing doses of
breast cancer drugs such as 5-FU (10-7, 10-6, 10-5, 10-4,
10-3 mol/L), Carboplatin (10-7, 10-6, 10-5, 10-4, mol/L),
Cisplatin (10-7, 10-6, 10-5, 10-4, 10-3 mol/L), Mitomycin-C
(10-8, 10-7, 10-6, 10-5, 10-4 mol/L) and Salinomycin (10-7,
10-6, 10-5, 10-4, 10-3 mol/L). ALDEFLUOR-positive cells
exhibited a significantly higher survival rate in the pres-
ence of drugs than the ALDEFLUOR-negative cells
(Figure 3A-E). Furthermore, we investigated the sensitiv-
ity of the two separated fractions of GI-101A breast
cancer cells to irradiation. Cell survival assays were per-
formed using increased doses from 0 Gy, 0.5 Gy, 1 Gy,
2 Gy and 4 Gy. We found that ALDEFLUOR-positive
cells showed an increased survival after irradiation treat-
ment in contrast to ALDEFLUOR-negative cell fraction,
which exhibited less resistance to radiation treatment
(Figure 3F).ALDEFLUOR-positive cells showed higher expression
levels of CD44, CD49f and CD24 surface marker proteins
than ALDEFLUOR-negative cells
In breast tumors, a CD44+CD24–/lowESA+ lineage subpo-
pulation was originally identified as the tumorigenic
(tumor-initiating) fraction. This conclusion is based more
on the ability of these cells to form tumors in NOD/SCID
mice when injected at very low numbers [6]. Human breast
cancer cell lines contain CD44+CD24–/lowESA+ cells that
exhibit characteristic stem cell features like anchorage-
independent growth at clonal densities, the ability to re-
construct the parental cell fractions, along with enhanced
tumorigenicity in mice [9,31]. The CD44+CD24–/low
phenotype also correlates to the enhanced expression of
pro-invasive genes such as IL-1α, IL-6, IL-8, urokinase
plasminogen activator [UPA] and the ability to form dis-
tant metastases [35-37]. In addition, tumorigenicity of pro-
spective breast CSCs has been linked to the expression of
α6 integrin (CD49f) [38] and β1 integrin [39]. To analyze
the CD44/CD24/CD49f expression in ALDEFLUOR-
positive and ALDEFLUOR-negative cells, we performed
an ALDEFLUOR assay followed by a CD44, CD24 and
CD49f immunostaining of ALDEFLUOR-positive and
ALDEFLUOR-negative cells (Figure 4). As shown in
Figure 4A-B, the percentage of CD44+ in ALDEFLUOR-
positive cells reached to 97.89% (Figure 4A gate Q1 +
Q2) or 94.99% (Figure 4B gate Q1 + Q2). However, the
percentage of CD44+ in ALDEFLUOR-negative cells
dropped to 85.23% or 81.83%. Similarly, the percentage
Figure 3 The response of sorted GI-101A ALDEFLUOR-positive and ALDEFLUOR-negative cells upon chemotherapy and ionizing
radiation treatments. Treatment of GI-101A ALDEFLUOR-positive and ALDEFLUOR-negative cells with (A) 5-FU, (B) Carboplatin, (C) Cisplatin, (D)
Mitomycin-C and (E) Salinomycin or (F) ionizing radiation. Means and 95% confidence intervals from three independent experiments are
shown (n = 3).
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(Figure 4B gate Q2 + Q3) and the percentage of CD49f+
in ALDEFLUOR-negative cells dropped to 90.8%. Fur-
thermore, there was no significant difference in the
CD24 expression between ALDEFLUOR-positive cells(98.92%, Figure 4A gate Q2 + Q3) and ALDEFLUOR-
negative cells (96.3%). Considering those surface mar-
ker expression in combination, the percentage of
CD44+CD24- in ALDEFLUOR-positive cells (0.79%,
Figure 4A gate Q1) was much lower than that in
Figure 4 Metastatic potential of GI-101A ALDEFLUOR-positive and ALDEFLUOR-negative cells. ALDEFLUOR assay based flow cytometry
analysis of human breast cancer stem cell surface markers (A) CD44/CD24 and (B) CD44/CD49f percentage of each population was summarized
in table. (C) The migration and invasion ability of ALDEFLUOR-positive and ALDEFLUOR-negative cells. Bars denote the standard error mean
(n = 3). The “*” indicate the significance between ALDEFLOUR-positive and ALDEFLUOR-negative cells.
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And the percentage of CD44+CD49f+ in ALDEFLUOR-
positive cells (94.2%, Figure 4B gate Q2) was higher than
that in ALDEFLUOR-negative cells (77.0%, Figure 4B gate
Q2). Considering both CD44 and CD49f could contributeto carcinoma progression and cancer metastases [40,41]
and the ALDEFLUOR-positive breast cancer cells have also
been reported to have cell invasion potential in vitro, which
is related to metastases in vivo [42,43], we also performed
Basement Membrane Extract (BME) invasion assay, using
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http://www.translational-medicine.com/content/10/1/16710% fetal bovine serum as attractant, to examine the ability
of ALDEFLUOR-positive and ALDEFLUOR-negative cells
from GI-101A to invade in matrix gels. As shown in
Figure 4C, we found that ALDEFLUOR-positive cells
demonstrated higher migration capability through BME
than the ALDEFLUOR-negative cells. These results sup-
ported the notion that GI-101A ALDEFLUOR-positive
cells exhibited invasive behavior.VACV GLV-1h68 strain replicates more efficiently in
ALDEFLUOR-positive cells than in ALDEFLUOR-negative
cells in culture
We compared replication efficiency of the vaccinia virus
strain GLV-1h68 in sorted ALDEFLUOR-positive and
ALDEFLUOR-negative cells. Both cell cultures were
infected with GLV-1h68 at an MOI of 0.01 or 10, and the
viral titer was determined at 1, 12, 24, 48 and 72 hours
post infection. We found that at 72 hours post infection,
the viral titer in ALDEFLUOR-positive cells was three
times higher at MOI of 0.01, and two times higher at
MOI of 10 when compared to ALDEFLUOR-negative
cells (Figure 5 A-B).VACV GLV-1h68 strain eradicates tumor xenografts
derived from ALDEFLUOR-positive cells more efficiently
than that derived from ALDEFLUOR-negative cells
To test the efficacy of oncolytic vaccinia virus GLV-1h68
strain, tumors were established in the mammary fat pads of
athymic nude mice by implantation of 5 × 103 sorted
ALDEFLUOR-positive and ALDEFLUOR-negative GI-
101A cells. To facilitate the comparison of results, each
mouse received two implantations, one into the left and an-
other into the right mammary fat pads, respectively (e.g.
5 × 103 ALDEFLUOR-positive cells were placed into right
fat pad and 5 × 103 ALDEFLUOR-negative cells into left
fad pad or vice versa). Twelve weeks after tumor cell im-
plantation, each mouse was administered with 5 × 106 pfu
of GLV-1h68 retro-orbitally. Both tumor size and virus
mediated GFP expression in tumors were monitored
weekly. Findings showed that the growth of both tumors
was significantly inhibited by virus treatment. However,
tumors derived from ALDEFLUOR-positive cells showed
a more tumor size reduction after virus treatments, as
opposed to tumors derived from ALDEFLUOR-negative
implants (Figure 5D). After comparison of the fluores-
cence images from the tumors, we also found that tumors
derived from ALDEFLUOR-positive cells originally had a
more efficient GLV-1h68 replication and more fluores-
cence than tumors derived from ALDEFLUOR-negative
cells (Figure 5C). More efficient virus replication resulted
in faster tumor regression and earlier fluorescence
detection.EMT induction of GI-101A cells resulted in cell population
with CD44+CD24+ESA+ and CD44+CD24-ESA+ markers
We examined whether the treatment of GI-101A cell line
with TGF-β1, similar to HMLE cell line [13,14], would lead
to an enrichment of mesenchymal cells by losing E-cadherin
and enhancing vimentin and fibronectin expression. We
found that twelve days after TGF-β1 treatment, EMT was
observed in this cell line (Additional file 5: Figure S5). In
comparison to GI-101A cells without TGF-β1 treatment,
the treated cells showed no difference in CD44 and ESA ex-
pression. However, the number of CD24+ cells (P5: 7.59%)
increased after TGF-β1 treatment, in contrast to cells with-
out TGF-β1 treatment (P5: 0.99%) (Figure 6A). Therefore
the treatment of GI-101A cells with TGF-β1 did, in fact, in-
duce a cell population with CD44+CD24+ESA+ marker ex-
pression as opposed to CD44+CD24-ESA+. To examine
whether CD44+CD24-ESA+ or CD44+CD24+ESA+ cells are
cancer stem-like cells and to further investigated their
tumorigenic potential, we implanted 10,000, 1,000, and 100
cells into the mammary fat pads of nude mice. Tumors were
detected in the mice injected with 10,000 CD44+CD24+ESA+
cells seven weeks after implantation. By 22 weeks after
implantation, the tumor size had reached 700 mm3 in
volume in contrast to 200 mm3 of tumors derived from
CD44+CD24-ESA+ cells (Figure 6B). Taken together, the
CD44+CD24+ESA+ cell population is 3.5 fold more tumori-
genic than the CD44+CD24-ESA+ cell population.
VACV GLV-1h68 strain shows higher replication in GI-
101A derived CD44+CD24+ESA+ cells resulting in
increased eradication of CD44+CD24+ESA+ cells derived
tumor xenografts.
We tested the ability of two VACVs to replicate in
TGF-β1 treated and untreated cells. Twelve days after
TGF-β1 treatment of cell lines, HMLE and GI-101A were
infected with either GLV-1h68 strain, which carries a
GFP fluorescent protein expression cassette, or GLV-
1h190 strain, similar to GLV-1h68, but expressing Tur-
boFP635 fluorescent protein. We found a preferential
VACV replication resulting in enhanced light emission in
the area of EMT cells (Additional file 6: Figure S6). To
document higher replication efficiency of GLV-1h68
strain in sorted CD44+CD24+ESA+ in comparison to
CD44+CD24-ESA+ cells, we performed a virus infection
followed by a replication assay. Both groups of cells were
infected with GLV-1h68 at an MOI of 0.01 or 10, and the
viral titers were determined at 1, 12, 24, 48 and 72 hours
post infection. At 72 hours post infection, the virus titer
in CD44+CD24+ESA+ cells was approximately fifteen
times higher at MOI 0.01, and ten times higher at MOI
10 in comparison to CD44+CD24-ESA+ cells (Figures 7A-
B). To test whether the higher replication efficiency would
result in enhanced oncolytic virus efficacy, we established
tumors in the mammary fat pads of athymic nude mice by
injection of 10,000 of sorted CD44+CD24+ESA+ and
Figure 5 GLV-1h68 strain preferentially replicates in ALDEFLUOR-positive cell population of GI-101A and enhanced replication in
the tumors derived from ALDEFLUOR-positive cells. Preferential replication of GLV-1h68 strain at (A) MOI0.01 and (B) MOI10 in
ALDEFLUOR-positive cell population of GI-101A breast cancer cells followed by viral titration in CV-1 cells. (C) Enhanced fluorescent GFP protein
expression in ALDEFLUOR-positive cells derived tumor in comparison to ALDEFLUOR-negative cells. (D) Enhanced inhibition of tumor growth in
ALDEFLUOR-positive cells derived tumors in comparison to ALDEFLUOR-negative cells derived tumors.
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genicity experiments described before, each mouse was
implanted with both cell fractions in these experiments,
one fraction (CD44+CD24+ESA+ ) in right mammary fat
pads and the other fraction (CD44+CD24-ESA+) in left,
with 10,000 sorted cells. Twenty-two weeks after cell im-
plantation, each mouse received 5 × 106 pfu of GLV-1h68
strain via the retro-orbital path. We monitored the tumor
size as well as tumor GFP expression weekly by fluores-
cent imaging (Figure 7C). We found that tumor growth
was generally inhibited after virus treatment in both left
and right breast tumors. However, tumors derived from
CD44+CD24+ESA+ cells showed a greater size reductionthan tumors derived from CD44+CD24-ESA+ cells
(Figure 7D). In summary, CD44+CD24+ESA+ cells did
support a more efficient virus replication and the higher
virus titer caused more rapid tumor elimination in nude
mice with CD44+CD24+ESA+ cells derived tumor
xenografts.
Discussion
The CSC hypothesis has fundamental implications in
cancer biology, in clinical cancer risk assessment, and in
the early detection, prognosis, and prevention of cancer.
The development of cancer therapeutics based on tumor
regression may have produced agents which kill
Figure 6 Separation of tumor-initiating cells from GI-101A upon an EMT induction and the tumorigenicity test. (A) Flow cytometry
sorting of tumor-initiating cells from GI-101A upon an EMT induction. CD44+CD24- (P4), CD44+CD24+ (P5) and ESA+ (P6) gates were
established based on uninduced cells. (B) Tumor forming capability of CD44+CD24+ESA+ and CD44+CD24-ESA+ cells were assessed in mice by
orthotopic implantation.
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become resistant and escape from drug therapy [5]. Cancer
stem cell identification was largely based on primary cells
as well as early passage of cell lines in a mouse xenograft
model [6,44]. However, the success of establishing breast
tumor xenografts for cancer stem cell identification has
been low mainly due to lack of breast cancer stem cell
markers. Cultured and passaged cell lines are readily avail-
able to provide more uniform cell populations in mouse
xenograft models without the influence of human healthy
tissues and human stroma [45,46]. These differentiated
cancer cells have a very small number (0.1-1%) of undif-
ferenated cells with cancer stem cell markers [12]. The
quantity of cancer stem cells derived from patient samples
is limited. Therefore, the establishment of relevant cancer
stem-like cell models in cell culture and in mouse tumor
xenograft models is critical for the study of cancer stem-
like cell characterization and therapy.
According to recently described findings [7], the cell
sorter based fluorescent ALDEFLUOR assay, in combin-
ation with ALDH1 immunostaining may prove to be critical
for the detection and isolation of CSCs from epithelial
tumor samples, thus facilitating CSC isolation/identification
in the clinical practice and on the cell culture level. In this
study, we have successfully identified, isolated and charac-
terized ALDEFLUOR-positive cells from GI-101A breast
cancer cell line with cancer stem-like characteristics. We
found that less than 5 × 103 ALDEFLUOR-positive cellsdid generate tumors six weeks after implantation in nude
mice and did grow to a size of 2,000 mm3 at nineteen
weeks. Cells with low levels of ALDH1 (ALDEFLUOR-
negative) initiated tumor growth at six weeks after implant-
ation in one mouse and did grow remarkably slower, reach-
ing a size of 200 mm3 at nineteen weeks. Judging by tumor
formation frequency and tumor growth, ALDEFLUOR-
positive cell exhibit more cancer stem-like cell growth
morphology than ALDEFLUOR-negative cells. These find-
ings were also confirmed by mammosphere formation assay
in cell culture. Furthermore, the ALDEFLUOR-positive
cells displayed enhanced resistance to five chemotherapy
drugs as well as to irradiation in cell cultures. Self-renewal
or asymmetrical division is also a unique feature associated
with stem cells/cancer stem cells. When the sorted
ALDEFLUOR-positive cells were cultured continually on
plates, the fraction of ALDEFLUOR-negative cells increased
from 17% to 80% approximately. Finally, the ratio between
ALDEFLUOR-positive and -negative cells reached to a
level, similar to that of GI-101A cell culture before sorting.
To further characterize ALDEFLUOR-positive cells, we
combined the ALDEFLUOR assay with known breast can-
cer stem cell surface marker analysis. Interestingly, we
found that the ALDEFLUOR-positive cell population exhib-
ited elevated CD44 and CD49f expression compared to the
ALDEFLUOR-negative cell population. These findings are
consistent with previously published data that both CD44
and CD49f marker proteins contribute to carcinoma
Figure 7 Enhanced replication of GLV-1h68 strain in CD44+CD24+ESA+ cell population of GI-101A and in the tumors derived from
CD44+CD24+ESA+ cells. Enhanced replication of GLV-1h68 strain at (A) MOI0.01 and (B) MOI10 in CD44+CD24+ESA+ cell population of EMT
induced GI-101A breast cancer cells followed by viral titration in CV-1 cells. (C) Enhanced fluorescent GFP protein expression in CD44+CD24+ESA+
cells derived tumor in comparison to CD44+CD24-ESA+ cells. (D) Enhanced inhibition of tumor growth in CD44+CD24+ESA+ derived tumors in
comparison to CD44+CD24-ESA+ cells derived tumors.
Wang et al. Journal of Translational Medicine 2012, 10:167 Page 12 of 15
http://www.translational-medicine.com/content/10/1/167progression and cancer metastases [38]. Cancer stem cells
may also be responsible for mediating tumor metastases
process. A link between cancer stem cells and secondary
tumor metastases was first suggested after the identification
of “stemness” and an 11-gene signature therapy resistant
profile of metastatic and primary tumors in prostate cancer
of a transgenic mouse model, as well as in cancer patients
[47]. This signature was also a powerful predictor of disease
recurrence, survival after therapy, and distant metastases in
a variety of cancer types. Here we also demonstrated
that ALDEFLUOR-positive cells migrated more effi-
ciently than ALDEFLUOR-negative cells in BME trans-
wells, indicating the increased metastatic potential of
GI-101A ALDEFLUOR-positive cells. Contrary to
current ‘CD44+CD24-/low centric’ thought regarding thedevelopmental plasticity of tumor-initiating mammary epi-
thelial cells [6,48], recent studies have revealed that not
only CD44+CD24-/low cells can give rise to CD44+CD24+
cells, as expected for a cancer stem cell [49], but that the
converse can also occur; CD44+CD24+ cells can give rise
to their CD44+CD24-/low counterparts and single cells from
either phenotype are capable of initiating tumors as xeno-
grafts with high efficiency [50]. Surprisingly, we also found
that ALDEFLUOR-positive cells had enhanced CD24 ex-
pression levels. These findings do contradict with known
and accepted human breast cancer stem cell markers,
which are elevated CD44 and reduced CD24. To confirm
that the expression of CD24 is also associated with
tumorigenicity, we established a CD44+CD24+ESA+ and
a CD44+CD24-ESA+ fraction from GI-101A cell line after
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CD24+ cells initiated tumors more efficiently than the
CD24- cells. This explains why ALDEFLUOR-negative
cells are less tumorigenic than ALDEFLUOR-positive
cells. Since ALDEFLUOR-positive cells showed also
higher expression of CD24, similarly to EMT cell popula-
tion, and both exhibited enhanced tumorigenicity, we
suggest that the elevated CD24 expression is a reliable
CSC marker in this cell line and that GI-101A cancer
stem-like cell markers are ALDH1+CD44+ CD24+ESA+.
Taken together, our results indicated the phenotype of
cancer stem cells is complex and the markers of cancer
stem cells vary among different cell sources.
We have reported earlier that after a single intravenous
injection of VACV GLV-1h68 strain, more than two dozen
human tumors and metastases in nude mice were effi-
ciently colonized and eradicated [51,52]. The importance
of cancer stem cells in tumor initiation and their resistance
to current therapies require the development of novel ther-
apies for both tumor elimination and prevention of tumor
recurrence. The data presented in this manuscript clearly
indicate that the VACV GLV-1h68 strain infects the
ALDH1+CD44+CD24+ESA+ cell population more effi-
ciently than the ALDH1-CD44+CD24-ESA+ cell popula-
tion. The more efficient infection resulted in enhanced
cytotoxicity and cell lysis in cell culture. Furthermore, this
virus also replicated more efficiently in tumors generated
from cancer stem-like cells. Lastly, the enhanced viral rep-
lication in the tumor xenograft derived from cancer stem-
like ALDH1+CD44+CD24+ESA+ cell implantation led to a
more efficient elimination of tumors, in comparison to
ALDH1-CD44+CD24-ESA+ cell derived xenografts. Based
on these experiments, either chemotherapy drug resistant
or irradiation resistant cancer stem-like cells were identi-
fied in cell culture and no further recurrence was seen in
treated mice carrying tumors derived from both
ALDEFLUOR-positive cell population and CD24+ cell
population.
Conclusion
In conclusion, the combination of ALDEFLUOR assay and
identification of cancer stem-like cells upon TGF-β1
induced EMT may allow the isolation of cancer stem-like
cells from tumor cell lines and tumor biopsies. Further, the
cancer stem-like cells showed elevated replication and
cytotoxicity of two VACV strains, GLV-1h68 and GLV-
1h190. Mice carrying cancer stem-like cell tumor xeno-
grafts were efficiently colonized and their tumors were
more rapidly eradicated than tumors grown from
ALDEFLUOR-negative and CD24- tumor cell population.
Therefore, VACV based oncolytic viral therapy may result
in efficient eradication of solid tumors, secondary metasta-
ses including cancer stem-like cells in tumors as well as
circulating tumor cells in blood.Additional files
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